Estee Lauder price target raised to $100 from $90 at Evercore ISI

Evercore ISI raised Estee Lauder (EL)'s price target to $100 and reiterated an Outperform rating, citing improving market share in China and the US, strong gross margins, and potential for 2026 EPS to significantly exceed consensus. This positive outlook follows EL's Q3 FY25 results, which saw adjusted operating income and EPS substantially beat expectations despite a 9% organic sales decline, alongside strategic expansion onto Amazon.ca. While Deutsche Bank also upgraded EL to Buy, Moody's downgraded the company due to slower credit metric recovery and market uncertainties, and Berenberg maintains a lower price target, reflecting a nuanced investment landscape for the cosmetics giant.

Analysis

Estee Lauder (EL) presents a complex investment case marked by conflicting signals, though the overall sentiment is moderately positive. On one hand, Evercore ISI has raised its price target to $100.00, maintaining an Outperform rating based on data suggesting improved market share in China and the U.S., and a belief that the consensus 2026 EPS estimate of $2.54 is significantly understated. This optimism is partially supported by the company's most recent quarterly results, where despite a 9% year-over-year drop in organic sales, adjusted operating income of $403 million and EPS of $0.65 substantially beat consensus estimates of $238 million and $0.31, respectively. This bottom-line outperformance indicates strong cost controls or margin management. Strategic initiatives, such as the expansion onto Amazon.ca, align with Deutsche Bank's rationale for upgrading the stock to Buy, citing a successful diversification strategy. On the other hand, significant headwinds persist. Moody's recently downgraded Estee Lauder's credit ratings due to a slower-than-expected recovery in credit metrics, highlighting balance sheet risk. Furthermore, analyst opinions are widely dispersed, with Berenberg maintaining a Hold rating and a much lower $61 price target, suggesting a lack of consensus on the company's near-term recovery trajectory.

Key Decisions for Investors

• Investors should weigh the significant bottom-line outperformance and bullish analyst targets against the persistent top-line sales decline and recent credit downgrade from Moody's.
• Monitor future earnings reports for a reversal in the organic sales trend and continued market share gains in key regions like the U.S. and China to validate the turnaround thesis.
• Given the wide dispersion in analyst price targets ($61 to $100), consider the stock's current valuation and risk profile, as the divergence signals significant uncertainty regarding the pace and success of the company's recovery.